Bristol-Myers Squibb Co.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.39B | $42.52B | $26.15B | $22.56B |
| United States | — | — | $31.58B | $31.80B | $29.66B | $26.55B | $14.97B | $12.49B |
| International | — | — | $13.43B | $14.36B | $16.72B | $15.96B | $11.17B | $10.07B |
| Cost of Revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B |
| Gross Profit | $34.26B | $34.33B | $34.31B | $36.02B | $36.45B | $30.75B | $18.07B | $16.09B |
| Gross Margin | 71.1% | 71.1% | 76.2% | 78.0% | 78.6% | 72.3% | 69.1% | 71.3% |
| Operating Expenses | ||||||||
| Research & Development | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B |
| SG&A Expense | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B |
| Operating Income | $9.33B | $-8.38B | $9.61B | $8.95B | $9.43B | $-5.45B | $5.63B | $6.15B |
| Operating Margin | 19.4% | -17.3% | 21.3% | 19.4% | 20.3% | -12.8% | 21.5% | 27.3% |
| Interest Expense | — | — | $1.17B | $1.23B | $1.33B | $1.42B | $656.0M | $183.0M |
| Pretax Income | $9.33B | $-8.38B | $8.44B | $7.71B | $8.10B | $-6.87B | $4.98B | $5.97B |
| Income Tax Expense | $2.27B | $554.0M | $400.0M | $1.37B | $1.08B | $2.12B | $1.52B | $1.02B |
| Net Income | $7.05B | $-8.95B | $8.03B | $6.33B | $6.99B | $-9.02B | $3.44B | $4.92B |
| Net Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | -21.2% | 13.2% | 21.8% |
| EPS (Basic) | $3.47 | $-4.41 | $3.88 | $2.97 | $3.15 | $-3.99 | $2.02 | $3.01 |
| EPS (Diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 | $-3.99 | $2.01 | $3.01 |
| Shares Outstanding (Basic) | 2.03B | 2.03B | 2.07B | 2.13B | 2.22B | 2.26B | 1.71B | 1.63B |
| Shares Outstanding (Diluted) | 2.04B | 2.03B | 2.08B | 2.15B | 2.25B | 2.26B | 1.71B | 1.64B |
| Dividends Per Share | $2.49 | $2.42 | $2.31 | $2.19 | $2.01 | $1.84 | $1.68 | $1.61 |